<DOC>
	<DOCNO>NCT00320749</DOCNO>
	<brief_summary>The primary purpose study define maximum tolerate dose combination docetaxel , gemcitabine , capecitabine patient pancreatic cancer . Adverse effect measure study participant . In addition , researcher assess data preliminary efficacy patient treatment approach .</brief_summary>
	<brief_title>Capecitabine , Docetaxel Gemcitabine Patients With Advanced Pancreas Cancer</brief_title>
	<detailed_description>Rationale : Single agent gemcitabine consider standard care patient advance pancreatic cancer . However , good treatment offer improve outcome need people disease . The combination docetaxel capecitabine show significant broad clinical activity variety tumor . Laboratory research combination capecitabine , docetaxel , gemcitabine indicate synergistic action tumor cell . The current study test combination patient . The drug administration schedule study aim maximize potential activation capecitabine docetaxel gemcitabine . Treatment : Study participant give docetaxel , gemcitabine , capecitabine . All study drug administer intravenous infusion three week cycle . Docetaxel give day 1 8 , gemcitabine day 8 15 , capecitabine day 8 21 . This schedule follow 1 week rest without administration study drug . Since primary goal study identify maximum tolerate dose study drug combination , patient enroll begin study receive low amount study drug compare patient enroll later study . Several test exams give throughout study closely monitor patient .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>adenocarcinoma pancreas prior chemo except adjuvant Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 peripheral neuropathy &lt; /= Gr . 1 Pregnant/lactating female Uncontrolled heart disease , diabetes , psychiatric disorder Therapeutic dose Warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced Pancreatic Cancer</keyword>
</DOC>